Get started
Author

Anne‐Renee Hartman

Observed names: A R Hartman, A. Hartman, A. R. Hartman, A.-R. Hartman, A.M. Hartman, A.R. Hartman, Anne-Renee Hartman, Anne-Renée Hartman, Anne-renee Hartman, Hartman, A., Hartman, Anne-Renee
Observed institutions: Fox Chase Cancer Center, Albert Einstein College of Medicine, Nebraska Medical Center, Beth Israel Deaconess Medical Center, Harvard University, Massachusetts General Hospital, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Stanford Medicine, Grail (United States), Alta Bates Summit Medical Center, Myriad Genetics, Adela (United States), Stanford University
ORCID: 0000-0003-3506-6440
Observed ORCID: 0000-0003-3506-6440
OpenAlex ID: A5073892003
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
2020 · M.C. Liu, G.R. Oxnard, et al. · Annals of Oncology · 1,479
PDF
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
2016 · Melinda L. Telli, Kirsten M. Timms, et al. · Clinical Cancer Research · 1,132
Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer
2016 · Nadine Tung, Nancy U. Lin, et al. · Journal of Clinical Oncology · 556
Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer
2017 · Matthew B. Yurgelun, Matthew H. Kulke, et al. · Journal of Clinical Oncology · 524
Detection and characterization of lung cancer using cell-free DNA fragmentomes
2021 · Dimitrios Mathios, Jakob Sidenius Johansen, et al. · Nature Communications · 474
PDF
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
2015 · Steven J. Isakoff, Erica L. Mayer, et al. · Journal of Clinical Oncology · 436
Frequency of mutations in individuals with breast cancer referred for BRCA 1 and BRCA 2 testing using next‐generation sequencing with a 25‐gene panel
2014 · Nadine Tung, Chiara Battelli, et al. · Cancer · 430
PDF
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
2018 · S. Loibl, K.E. Weber, et al. · Annals of Oncology · 295
BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study
2014 · David B. Zhen, Kari G. Rabe, et al. · Genetics in Medicine · 295
PDF
Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome
2015 · Matthew B. Yurgelun, Brian Allen, et al. · Gastroenterology · 260
PDF
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1 / 2 Mutation–Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105
2015 · Melinda L. Telli, Kristin C. Jensen, et al. · Journal of Clinical Oncology · 233
PDF
BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair
2002 · Anne-Renee Hartman, James M. Ford · Nature Genetics · 233
Prevalence of BRCA mutations in an unselected population of triple‐negative breast cancer
2011 · Anne‐Renee Hartman, Rajesh R. Kaldate, et al. · Cancer · 221
PDF
Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway
2006 · Deborah Chirnomas, Toshiyasu Taniguchi, et al. · Molecular Cancer Therapeutics · 207
Breast and Ovarian Cancer Penetrance Estimates Derived From Germline Multiple-Gene Sequencing Results in Women
2017 · Allison W. Kurian, Elisha Hughes, et al. · JCO Precision Oncology · 195
Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma
2015 · Loren E. Clarke, M.B. Warf, et al. · Journal of Cutaneous Pathology · 158
PDF
Prevalence of germ-line mutations in cancer genes among pancreatic cancer patients with a positive family history
2017 · Kari G. Chaffee, Ann L. Oberg, et al. · Genetics in Medicine · 144
PDF
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)
2017 · P. Sharma, W.E. Barlow, et al. · Annals of Oncology · 124
PDF
Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer
2017 · Melinda L. Telli, Jessica Hellyer, et al. · Breast Cancer Research and Treatment · 119
Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort
2016 · Kari L Ring, Amanda S Bruegl, et al. · Modern Pathology · 114
PDF
New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening
2022 · Allan Hackshaw, Christina A. Clarke, et al. · Cancer Cell · 101
Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma
2004 · Anne‐Renee Hartman, Bruce L. Daniel, et al. · Cancer · 78
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)
2015 · Virginia G. Kaklamani, Jacqueline S. Jeruss, et al. · Breast Cancer Research and Treatment · 74
Projected Reductions in Absolute Cancer–Related Deaths from Diagnosing Cancers Before Metastasis, 2006–2015
2020 · Christina A. Clarke, Earl Hubbell, et al. · Cancer Epidemiology Biomarkers & Prevention · 73
Tumor BRCA1 Reversion Mutation Arising during Neoadjuvant Platinum-Based Chemotherapy in Triple-Negative Breast Cancer Is Associated with Therapy Resistance
2017 · Anosheh Afghahi, Kirsten M. Timms, et al. · Clinical Cancer Research · 73
Works count: 164
Citation count: 9,102
H-index: 36
I10-index: 54
Year
Topic
Type